explore -WSS

explore

author：comprehensive 2025-09-27 12:47:59 - browse：32

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Scientists successfully use ultrasound imaging to map brain activity

WSS

Chinese researcher claims birth of first gene

iTeos Therapeutics debuts first data on TIGIT

Biotech investment managers search for lucrative opportunities

Scientists successfully use ultrasound imaging to map brain activity

Akili, maker of video game for ADHD, to be acquired for 34 million

Readout LOUD podcast, live from the STAT Breakthrough Summit East

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Startling documents reveal new facets of Sacklers' opioid empire

How to save PrEP access — and even expand it

Heat waves linked to early deliveries, preterm births in new study

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Bring on the sabbaticals for nurses

Moonlake's readout produced a cash windfall. Risks remain

Asbestos ban is immediate, but health effects will linger for decades

Sports medicine is finally prioritizing gender equality

Pfizer, Moderna say biotech, pharma drug development is a sprint

Wikipedia

This gene therapy has record $4.25 million price. It's saved children.

AI used to predict Covid

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Startling documents reveal new facets of Sacklers' opioid empire

Addiction doctors spar with methadone clinics over legislation

Lab trade group sues FDA to halt regulation of lab

leisure time

Wikipedia

entertainment

focus